{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T07:26:55Z","timestamp":1695540415489},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,4,23]],"date-time":"2008-04-23T00:00:00Z","timestamp":1208908800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathol. Oncol. Res."],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1007\/s12253-008-9043-y","type":"journal-article","created":{"date-parts":[[2009,1,9]],"date-time":"2009-01-09T22:04:33Z","timestamp":1231538673000},"page":"411-421","source":"Crossref","is-referenced-by-count":7,"title":["Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)\u2014Clinicopathological Features Based on the Data of Two Hungarian Lymphoma Centres"],"prefix":"10.1007","volume":"14","author":[{"given":"\u00c1.","family":"Ill\u00e9s","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zs","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"T\u00f3th","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Rosta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zs","family":"Milt\u00e9nyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zs","family":"Moln\u00e1r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,4,23]]},"reference":[{"key":"9043_CR1","first-page":"465","volume":"64","author":"H Jackson","year":"1937","unstructured":"Jackson H (1937) Classification and prognosis of Hodgkin\u2019s disease and allied disorders. Surg Gynecol Obstet 64:465","journal-title":"Surg Gynecol Obstet"},{"key":"9043_CR2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJM194407132310201","volume":"230","author":"H Jackson","year":"1944","unstructured":"Jackson H, Parker F (1944) Hodgkin\u2019s disease. I. General considerations. N Eng J Med 230:35\u201344","journal-title":"N Eng J Med"},{"key":"9043_CR3","first-page":"1063","volume":"26","author":"RJ Lukes","year":"1966","unstructured":"Lukes RJ, Butler JJ (1966) The pathology and nomenclature of Hodgkin\u2019s disease. Cancer Res 26:1063\u20131083","journal-title":"Cancer Res"},{"key":"9043_CR4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/1097-0142(196603)19:3<317::AID-CNCR2820190304>3.0.CO;2-O","volume":"19","author":"RJ Lukes","year":"1966","unstructured":"Lukes RJ, Butler JJ, Hicks EB (1966) Natural history of Hodgkin\u2019s disease as related to its pathologic picture. Cancer 19:317","journal-title":"Cancer"},{"key":"9043_CR5","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.semradonc.2007.02.004","volume":"17","author":"HK Tsai","year":"2007","unstructured":"Tsai HK, Mauch PM (2007) Nodular lymphocyte-predominant Hodgkin lymphoma. Semin Rad Oncol 17:184\u2013189","journal-title":"Semin Rad Oncol"},{"key":"9043_CR6","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","volume":"84","author":"NL Harris","year":"1994","unstructured":"Harris NL, Jaffe ES, Stein H, et al (1994) A revised European\u2013American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84:1361\u20131362","journal-title":"Blood"},{"key":"9043_CR7","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","volume":"17","author":"NL Harris","year":"1999","unstructured":"Harris NL, Jaffe ES, Diebold J et al (1999) World Health Organization Classification of neoplastic diseases of hematopoetic and lymphoid tissues: Report of the Clinical Advisory Commitee Meeting\u2014Airlie House, Virginia, November 1997. J Clin Oncol 17:3835\u20133849","journal-title":"J Clin Oncol"},{"key":"9043_CR8","doi-asserted-by":"crossref","unstructured":"Nogov\u00e1 L, Rudiger T, Engert A (2006) Biology, clinical course and management of nodular lymphocyte-predominant Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2006:266\u2013272","DOI":"10.1182\/asheducation-2006.1.266"},{"key":"9043_CR9","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1200\/JCO.1999.17.3.776","volume":"17","author":"V Diehl","year":"1999","unstructured":"Diehl V, Sextro M, Franklin J et al (1999) Clinical presentation, course and prognostic factors in lymphocyte-predominant Hodgkin\u2019s disease and lymphocyte-rich classical Hodgkin\u2019s disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin\u2019s Disease. J Clin Oncol 17:776\u2013783","journal-title":"J Clin Oncol"},{"key":"9043_CR10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0165-5876(02)00176-3","volume":"65","author":"J Hicks","year":"2002","unstructured":"Hicks J, Flaitz C (2002) Progressive transformation of germinal centers: review of histopathologic and clinical features. Int J Ped Otorhinolar 65:195\u2013202","journal-title":"Int J Ped Otorhinolar"},{"issue":"10","key":"9043_CR11","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1182\/blood-2003-02-0626","volume":"102","author":"L Boudov\u00e1","year":"2003","unstructured":"Boudov\u00e1 L, Torlakovic E, Delabie J et al (2003) Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell\/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell\/histiocyte-rich B-cell lymphoma. Blood 102(10):3753\u20133758","journal-title":"Blood"},{"key":"9043_CR12","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","volume":"7","author":"TA Lister","year":"1989","unstructured":"Lister TA, Crowther D, Sutcliffe SB, et al (1989) Report of a committee convened to discuss the evolution and staging of patients with Hodgkin\u2019s disease: Cotswolds meeting. J Clin Oncol 7:1630\u20131636","journal-title":"J Clin Oncol"},{"issue":"1","key":"9043_CR13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood.V73.1.47.47","volume":"73","author":"M Tubiana","year":"1989","unstructured":"Tubiana M, Henry-Amar M, Carde P, et al (1989) Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin\u2019s disease. The EORTC Lymphoma Group controlled clinical trials: 1964\u20131987. Blood 73(1):47\u201356","journal-title":"Blood"},{"key":"9043_CR14","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","volume":"339","author":"D Hasenclever","year":"1998","unstructured":"Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin\u2019s disease. N Eng J Med 339:1506\u20131514","journal-title":"N Eng J Med"},{"issue":"suppl.","key":"9043_CR15","first-page":"80","volume":"2","author":"Gy Varga","year":"1998","unstructured":"Varga Gy et al (1998) Hodgkin\u2019s disease. Magy Belorv Arch 2(suppl.):80\u201381","journal-title":"Magy Belorv Arch"},{"key":"9043_CR16","first-page":"133","volume-title":"Hematol\u00f3giai betegs\u00e9gek kezel\u00e9s\u00e9nek m\u00f3dszertana","author":"\u00c1 Ill\u00e9s","year":"2004","unstructured":"Ill\u00e9s \u00c1, Udvardy M, \u00c9sik O, et al (2004) Hodgkin\u2019s disease (HL). In: Lehoczky D (ed) Hematol\u00f3giai betegs\u00e9gek kezel\u00e9s\u00e9nek m\u00f3dszertana. Documed, Budapest, pp 133\u2013140"},{"key":"9043_CR17","first-page":"153","volume":"37","author":"\u00c1 Ill\u00e9s","year":"2004","unstructured":"Ill\u00e9s \u00c1, Keresztes K, Milt\u00e9nyi Zs et al (2004) Epidemiologic and treatment data on Hodgkin\u2019s disease in Hungary\u2014report of the Hodgkin\u2019s Disease Work Group. Hematol-Transzfuziol 37:153\u2013163","journal-title":"Hematol-Transzfuziol"},{"key":"9043_CR18","first-page":"240","volume-title":"Pathology and genetics of tumors of haematopoetic and lymphoid tissues","author":"E Jaffe","year":"2001","unstructured":"Jaffe E, Harris NL, Stein H et al (2001) Pathology and genetics of tumors of haematopoetic and lymphoid tissues. IARC, Lyon, France pp 240\u2013243"},{"key":"9043_CR19","first-page":"2","volume":"5","author":"A Rahemtullah","year":"2007","unstructured":"Rahemtullah A, Reichard KK, Dorn ME et al (2007) Double-positive CD4+CD8+ T-cell populations in nodular lymphocyte predominant Hodgkin lymphoma: further charachterization and relationship to other entities. Haematologica Suppl 5:2","journal-title":"Haematologica Suppl"},{"issue":"5","key":"9043_CR20","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1093\/annonc\/9.suppl_5.S45","volume":"9","author":"NL Harris","year":"1998","unstructured":"Harris NL (1998) The many faces of Hodgkin\u2019s disease around the world: what have we learned from its pathology? Ann Oncol 9(5):S45\u2013S56","journal-title":"Ann Oncol"},{"issue":"13","key":"9043_CR21","first-page":"651","volume":"143","author":"L Pajor","year":"2002","unstructured":"Pajor L (2002) Hodgkin lymphomas: current presentation of pathogenesis and patomorphology. Orv Hetil 143(13):651\u2013661","journal-title":"Orv Hetil"},{"key":"9043_CR22","doi-asserted-by":"crossref","unstructured":"Wang SA, Olson N, Zukerberg L et al (2006) Splenic marginal zone lymphoma with micronodular T-cell rich B-cell lymphoma. Am J Surg Pathol 30:128\u2013132","DOI":"10.1097\/01.pas.0000174268.22331.8d"},{"key":"9043_CR23","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/00000478-200307000-00005","volume":"27","author":"A Dogan","year":"2003","unstructured":"Dogan A, Burke JS, Goteri G et al (2003) Micronodular T-cell\/histiocyte-rich large B-cell lymphoma of the spleen. Histology, immunophenotype and differential diagnosis. Am J Surg Pathol 27:903\u2013911","journal-title":"Am J Surg Pathol"},{"key":"9043_CR24","first-page":"284","volume-title":"Non-Hodgkin lymphoma","author":"S Fekete","year":"1998","unstructured":"Fekete S, Matolcsy A (1998) A Hodgkin-k\u00f3r \u00e9s a non-Hodgkin lymphoma hat\u00e1rter\u00fcletei. In: P\u00e1l\u00f3czi K, Kel\u00e9nyi G (eds) Non-Hodgkin lymphoma. Springer, Budapest, pp 284\u2013289"},{"issue":"10","key":"9043_CR25","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1097\/00000478-200310000-00007","volume":"27","author":"Z Fan","year":"2003","unstructured":"Fan Z, Natkunam Y, Bair E et al (2003) Characterization of variant patterns of nodular lymphocyte predominant Hodgkin-lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol 27(10):1346\u20131356","journal-title":"Am J Surg Pathol"},{"key":"9043_CR26","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1600-0609.2005.00462.x","volume":"66","author":"L Nogova","year":"2005","unstructured":"Nogova L, Reineke T, Josting A, et al (2005) Lymphocyte predominant and classical Hodgkin\u2019s lymphoma-comparison of outcomes. Eur J Hematol Suppl 66:106\u2013110","journal-title":"Eur J Hematol Suppl"},{"key":"9043_CR27","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.hoc.2007.07.004","volume":"21","author":"V Diehl","year":"2007","unstructured":"Diehl V, Engert A, Re D (2007) New Strategies for the treatment of advanced-stage Hodgkin\u2019s lymphoma. Hematol Oncol Clin N Am 21:897\u2013914","journal-title":"Hematol Oncol Clin N Am"},{"issue":"Suppl.2","key":"9043_CR28","first-page":"77","volume":"2","author":"JM Cosset","year":"1991","unstructured":"Cosset JM, Henry-Amar M, Meerwaldt JH (1991) Long-term toxicity of early stages of Hodgkin\u2019s disease therapy: the EORTC experience. EORTC Lymphoma Cooperative Group. Ann Oncol 2(Suppl.2):77\u201382","journal-title":"EORTC Lymphoma Cooperative Group. Ann Oncol"},{"key":"9043_CR29","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/hon.782","volume":"24","author":"M Hutchings","year":"2006","unstructured":"Hutchings M, Loft A, Hansen M (2006) Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. Hematol Oncol 24:146\u2013150","journal-title":"Hematol Oncol"},{"key":"9043_CR30","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/cncr.21303","volume":"104","author":"A Wirth","year":"2005","unstructured":"Wirth A, Yuen K, Barton M (2005) Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australian Radiation Oncology Lymphoma Group. Cancer 104:1221\u201312229","journal-title":"Cancer"},{"key":"9043_CR31","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1093\/annonc\/mdi323","volume":"16","author":"L Nogova","year":"2005","unstructured":"Nogova L, Reineke T, Eich HT (2005) Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin\u2019s lymphoma: a retrospective analysis from German Hodgkin Study Group (GHSG). Ann Oncol 16:1683\u20131687","journal-title":"Ann Oncol"},{"key":"9043_CR32","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1002\/cncr.10404","volume":"94","author":"RB Wilder","year":"2002","unstructured":"Wilder RB, Schlembach PJ, Jones D (2002) European Organization for Research and Treatment of Cancer and Groupe d\u2019Etude des Lymphomes de l\u2019Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. Cancer 94:1731\u20131738","journal-title":"Cancer"},{"key":"9043_CR33","first-page":"27","volume":"5","author":"KJ Savage","year":"2007","unstructured":"Savage KJ, Hoskins P, Klasa R et al (2007) ABVD chemotherapy is essential for optimal treatment of limited stage nodular lymphocyte predominant Hodgkin lymphoma. Hematology Suppl 5:27","journal-title":"Hematology Suppl"},{"key":"9043_CR34","first-page":"18","volume":"5","author":"RP M\u00fcller","year":"2007","unstructured":"M\u00fcller RP, Eich HT (2007) Dose and field size, the GSHG experience. Hematology Suppl 5:18","journal-title":"Hematology Suppl"},{"key":"9043_CR35","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2002-08-2644","volume":"101","author":"BC Ekstrand","year":"2003","unstructured":"Ekstrand BC, Lucas JB, Horwitz SM, et al (2003) Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 101:4285\u20134289","journal-title":"Blood"},{"key":"9043_CR36","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1182\/blood-2007-03-078725","volume":"1","author":"H Schulz","year":"2008","unstructured":"Schulz H, Rehwald U, Morschhauser F et al (2008) Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase-II trial by German Hodgkin Lymphoma Study Group (GHSG). Blood 1:109\u2013111","journal-title":"Blood"},{"key":"9043_CR37","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood.V108.11.2742.2742","volume":"108","author":"A Younes","year":"2006","unstructured":"Younes A, Fayad LY, Goy A, et al (2006) Results of rituximab plus ABVD in 65 newly diagnosed patients with classical Hodgkin lymphoma: improvement of event free survival (EFS) in all international prognostic score (IPS) groups [abstract]. Blood 108:2742","journal-title":"Blood"},{"key":"9043_CR38","first-page":"33","volume":"5","author":"A Younes","year":"2007","unstructured":"Younes A, Fayad LY, Goy A et al (2007) Phase-II study of rituximab plus ABVD for the treatment of newly diagnosed patients with advanced stage classical Hodgkin lymphoma (HL). Hematology Suppl 5:33","journal-title":"Hematology Suppl"},{"key":"9043_CR39","first-page":"12","volume":"5","author":"RF Ambinder","year":"2007","unstructured":"Ambinder RF, Jones RJ, Matsui W (2007) Hodgkin\u2019s lymphoma (HL): evidence for a cancer stem cell and therapeutic implications. Hematology Suppl 5:12","journal-title":"Hematology Suppl"},{"key":"9043_CR40","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1182\/blood.V86.6.2312.bloodjournal8662312","volume":"86","author":"RS Wickert","year":"1995","unstructured":"Wickert RS, Weisenburger DD, Tierens A et al (1995) Clonal relationship between lymphocytic predominance Hodgkin\u2019s disease and concurrent or subsequent large-cell lymphoma of B lineage. Blood 86:2312\u20132320","journal-title":"Blood"},{"key":"9043_CR41","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1182\/blood.V88.2.657.bloodjournal882657","volume":"88","author":"TC Greiner","year":"1996","unstructured":"Greiner TC, Gascoyne RD, Anderson ME et al (1996) Nodular lymphocyte-predominant Hodgkin\u2019s disease associated with large-cell lymphoma: analysis of Ig gene rearrangements by V-J polymerase chain reaction. Blood 88:657\u2013666","journal-title":"Blood"},{"key":"9043_CR42","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.hoc.2007.06.016","volume":"21","author":"S Mathas","year":"2007","unstructured":"Mathas S (2007) The pathogenesis of classical Hodgkin\u2019s lymphoma: a model for B-cell plasticity. Hematol Oncol Clin N Am 21:787\u2013804","journal-title":"Hematol Oncol Clin N Am"},{"key":"9043_CR43","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000206014","volume":"76","author":"BB Mittal","year":"1986","unstructured":"Mittal BB, Nalesnik M, Composite (1986) lymphoma (Hodgkin\u2019s and non-Hodgkin\u2019s) of the spleen in a previously untreated patient. Acta Hematol 76:29\u201332","journal-title":"Acta Hematol"},{"key":"9043_CR44","first-page":"599","volume":"12","author":"JT Sundeen","year":"1988","unstructured":"Sundeen JT, Cossman J, Jaffe ES (1988) Lymphocyte predominant Hodgkin\u2019s disease nodular subtype with coexistent \u2018large cell lymphoma\u2019. Histological progression or composite malignancy? Am J Surg Pathol 12:599\u2013606","journal-title":"Am J Surg Pathol"},{"key":"9043_CR45","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1080\/1042819031000149421","volume":"45","author":"JZ Huang","year":"2004","unstructured":"Huang JZ, Weisenburger DD, Vose JM, et al (2004) Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin lymphoma: a report of 21 cases from the Nebraska Lymphoma Study Group. Leuk Lymph 45:1551\u20131557","journal-title":"Leuk Lymph"}],"container-title":["Pathology &amp; Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-008-9043-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12253-008-9043-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-008-9043-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T14:36:53Z","timestamp":1589467013000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12253-008-9043-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,23]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["9043"],"URL":"https:\/\/doi.org\/10.1007\/s12253-008-9043-y","relation":{},"ISSN":["1219-4956","1532-2807"],"issn-type":[{"value":"1219-4956","type":"print"},{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,23]]}}}